希望之光-多发性骨髓瘤患者的起点 Teresa女士坐在单采室的舒适座位上,注视着护士轻柔地在她手臂上穿刺,抽取宝贵的白细胞样本。这些白细胞将成为CAR-T治疗的核心材料,经过工程化后,将再次注入她体内,成为对抗癌症的力量源泉。 手术室内,机器轻声运转,精密地分离出Teresa身体中的T细胞。这些细胞,此前在她的身体内忠实执行着保护机体的职责,如今将被重新教育,成为一支针对癌细胞的精确打击队伍。Teresa闭上眼睛,心中默默祈祷这次单采能为她的身体注入战斗的力量,将病魔赶出她的生命。 单采过程持续了几个小时,医护人员细心地监控着每一个步骤,确保采集到足够数量和质量的细胞。这些细胞的提取不仅是技术上的挑战,更是对医疗团队专业能力的严格考验。 完成单采后,Teresa感到轻松了一些。她知道,这只是漫长治疗过程中的第一步,但也是希望之光的重要起点。在单采室内,她感受到了医护团队的温暖和专业,这让她对未来的治疗充满信心和希望。 回到病房,Teresa在床上轻轻闭上了眼睛。她思考着接下来的日子将如何展开,希望这次单采能为她带来战胜疾病的力量,让她重获新生。 单采,作为治疗之旅的第一步,铸就了Teresa勇敢抗癌的新篇章,也为她未来的康复之路点燃了希望的火光。 #希望之路 #ThePathOfHope #与癌症抗争 #FightingCancer #CART治疗之旅 #JourneyOfCARTTherapy #携手同济 #TogetherWithTongji #全人源CART #FullyHumanCART #FUCASO希望 #HopeWithFUCASO #EquecelApproval #健康重生 #HealthReborn #共同祈愿 #UnitedInPrayer #MultipleMyeloma
Myeloma
Interpretation of Hot Topics Conerning Mutiple Myeloma Patients: “What are the adverse reactions after CAR-T cell reinfusion?” Process Diagram for Myeloma Patients Receiving CAR-T Therapy RRMM(Relapsed/Refractory Multiple Myeloma) Unveiling how the “million-dollar anti-cancer shot” saves patients with recurrent and refractory bone tumors! Taking you through the entire process of CAR-T therapy. CAR-T细胞回输后有哪些不良反应? 骨髓瘤患者接受CAR-T治疗的流程图 权威专家解读之骨髓瘤全程管理 Expert Read More
2024 EBMT : China’s First RRMM CAR-T Therapy Equecabtagene Autoleucel: Efficacy Unaffected by Patients’ Baseline sBCMA Plasma Levels In recent years, CAR-T cell therapy targeting BCMA has emerged as a groundbreaking treatment for multiple myeloma, offering new hope to patients. At the 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, held from April Read More
**2024 EHA | Breaking Through Multiple Myeloma Treatment Bottlenecks: Significant Advances of Equecabtagene Autoleucel in High-Risk NDMM Patients** Multiple Myeloma (MM) is a malignant plasma cell disorder and one of the most common hematologic malignancies. In China, approximately 20,000 new cases of newly diagnosed multiple myeloma (NDMM) are reported annually, with a median age at Read More
###IMWG Releases 2024 RRMM CAR-T Guidelines: Equecabtagene Autoleucel Becomes China’s First Included CAR-T Therapy ###EquecabtageneAutoleucel: Leading China’s CAR-T Therapy to Global Breakthroughs In the latest guidelines released by the International Myeloma Working Group (IMWG) in 2024, Equecabtagene Autoleucel, a CAR-T therapy independently developed in China, has been officially included. This marks the first and only Read More
#EBMT / The Success Story of Equecabtagene Autoleucel: The World’s First Fully Human CAR-T for Multiple Myeloma In recent years, CAR-T cell therapy has made groundbreaking progress in the field of relapsed/refractory multiple myeloma (RRMM), offering hope to patients struggling with limited treatment options. Recent data shows that Equecabtagene Autoleucel achieved an impressive complete response (CR) Read More
**The Journey of an Indian Cancer Patient Seeking Treatment in China: Gratitude to Be Brought Back to India** “Before coming to China for treatment, I was filled with worries. My condition was not optimistic, and I was afraid I might never see my family again… But after arriving here, everyone I met was so warm Read More
22 Days from Desperation to Rebirth! Chinese CAR-T Therapy Creates Survival Miracle for Thai Multiple Myeloma Patient Subtitle: Fighting for Love! A story of miraculous rebirth after all treatment options failed for a late-stage multiple myeloma patient in Thailand, who underwent CAR-T therapy in China. Preface: When all treatment options had been exhausted, cancer progressed Read More
Interpretation of Hot Topics Conerning Relapsed/Refractory Mutiple Myeloma Patients: What other treatment options are available for patients with relapsed Multiple Myeloma? How effective is the new drug treatment for the first relapse of Multiple Myeloma? What treatment options are available for initial relapse of multiple myeloma? What are the treatment goals for Relapsed/Refractory Multiple Myeloma Read More
**Заголовок: Ключевые этапы прецизионного лечения: подробный обзор инфузии CAR-T у российского пациента в шанхайской больнице Jiahui** Владимир Борзёнков, 68-летний пациент из Санкт-Петербурга, Россия, недавно завершил ключевой этап терапии CAR-T — реинфузию — в международной больнице Jiahui в Шанхае. Этот важный шаг включает повторное введение Т-клеток, которые были генетически модифицированы для распознавания и атаки определённых раковых Read More
Key Steps in Precision Treatment: A Detailed Overview of CAR-T Infusion for a Russian Patient at Jiahui in Shanghai** Vladimir Borzenkov, a 68-year-old patient from St. Petersburg, Russia, recently completed the core phase of CAR-T therapy—reinfusion—at Jiahui International Hospital in Shanghai. This crucial step involves reinfusing T-cells, which have been genetically modified to recognize and Read More
Based on these data, a second-generation bispecific BC19 CAR targeting BCMA and CD19 was designed. This trial reports the preclinical results of BC19 CAR-T cells and the outcomes of R/R MM patients treated in the phase I/II trial.